KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Raw Materials (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Raw Materials data on record, last reported at $38.6 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 14.65% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $38.6 million, down 14.65%, while the annual FY2025 figure was $38.6 million, 14.65% down from the prior year.
  • Raw Materials reached $38.6 million in Q4 2025 per PACB's latest filing, down from $41.8 million in the prior quarter.
  • Across five years, Raw Materials topped out at $46.0 million in Q2 2025 and bottomed at $4.5 million in Q1 2021.
  • Average Raw Materials over 5 years is $25.1 million, with a median of $24.9 million recorded in 2023.
  • Peak YoY movement for Raw Materials: surged 262.42% in 2022, then decreased 14.65% in 2025.
  • A 5-year view of Raw Materials shows it stood at $8.0 million in 2021, then soared by 202.0% to $24.1 million in 2022, then surged by 34.36% to $32.4 million in 2023, then soared by 39.58% to $45.3 million in 2024, then fell by 14.65% to $38.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $38.6 million in Q4 2025, $41.8 million in Q3 2025, and $46.0 million in Q2 2025.